{"id":745289,"date":"2016-12-06T08:20:00","date_gmt":"2016-12-06T08:20:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/updated-keytruda-pembrolizumab-data-in-small-cell-lung-cancer-and-mesothelioma-presented-at-17th-world-conference-on-lung-cancer\/"},"modified":"2025-11-07T01:25:29","modified_gmt":"2025-11-07T06:25:29","slug":"updated-keytruda-pembrolizumab-data-in-small-cell-lung-cancer-and-mesothelioma-presented-at-17th-world-conference-on-lung-cancer","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/updated-keytruda-pembrolizumab-data-in-small-cell-lung-cancer-and-mesothelioma-presented-at-17th-world-conference-on-lung-cancer\/","title":{"rendered":"Updated KEYTRUDA\u00ae (pembrolizumab) Data in Small Cell Lung Cancer and Mesothelioma Presented at 17th World Conference on Lung Cancer"},"content":{"rendered":"<p class=\"bwalignc\">       Findings in Small Cell Lung Cancer and Malignant Pleural Mesothelioma        Show Overall Response Rates of 33.3 Percent and 20.0 Percent,        Respectively, in KEYNOTE-028     <\/p>\n<p class=\"bwalignc\">       Long-Term Data Demonstrate Durable Responses in Difficult-to-Treat        Cancers     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that updated findings from the phase 1b KEYNOTE-028<br \/>\n      study investigating the use of KEYTRUDA<sup>\u00ae<\/sup> (pembrolizumab), the<br \/>\n      company\u2019s anti-PD-1 therapy, in previously treated patients with<br \/>\n      advanced small cell lung cancer (SCLC) and malignant pleural<br \/>\n      mesothelioma, showed clinical activity and durable responses in some<br \/>\n      patients. These data were featured in oral presentations at the 17<sup>th<\/sup><br \/>\n      World Conference on Lung Cancer hosted by the International Association<br \/>\n      for the Study of Lung Cancer.\n    <\/p>\n<p>\n      \u201cAs data from our initial trials exploring KEYTRUDA mature, we are<br \/>\n      encouraged to see durable clinical activity in difficult-to-treat<br \/>\n      cancers such as small cell lung cancer and malignant pleural<br \/>\n      mesothelioma, where new treatments are clearly needed,\u201d said Dr. Roger<br \/>\n      Dansey, senior vice president and therapeutic area head, oncology<br \/>\n      late-stage development, Merck Research Laboratories. \u201cWith our extensive<br \/>\n      immuno-oncology research program, we are developing KEYTRUDA across a<br \/>\n      range of thoracic malignancies, and we have additional studies underway<br \/>\n      in these two cancer types.\u201d\n    <\/p>\n<p>\n      KEYNOTE-028 is an ongoing multi-cohort, non-randomized Phase 1b basket<br \/>\n      trial evaluating the safety, tolerability, and anti-tumor activity of<br \/>\n      KEYTRUDA monotherapy (10 mg\/kg dosed every two weeks) in more than 450<br \/>\n      patients with PD-L1 positive tumors across 20 different types of cancer.<br \/>\n      PD-L1 positivity was defined as expression in one percent or more of<br \/>\n      tumor and associated inflammatory cells or positive staining in stroma.<br \/>\n      The primary outcome measure is overall response rate (ORR), with<br \/>\n      secondary outcome measures of progression-free survival (PFS), overall<br \/>\n      survival (OS), and duration of response.\n    <\/p>\n<p>\n      The KEYTRUDA (pembrolizumab) clinical development program includes more<br \/>\n      than 30 tumor types in nearly 400 clinical trials, including more than<br \/>\n      200 trials that combine KEYTRUDA with other cancer treatments. Merck has<br \/>\n      initiated a phase 2 trial, KEYNOTE-158, to further evaluate KEYTRUDA in<br \/>\n      advanced solid tumors including SCLC and malignant pleural mesothelioma.\n    <\/p>\n<p>\n      <b>Results from KEYNOTE-028 SCLC Cohort (Abstract #OA05.01)<\/b>\n    <\/p>\n<p>\n      Data from the SCLC cohort of the KEYNOTE-028 trial were presented in an<br \/>\n      oral presentation on Dec. 5 by Dr. Patrick Ott, Dana-Farber Cancer<br \/>\n      Institute.\n    <\/p>\n<p>\n      Updated findings from 24 heavily pre-treated patients with advanced SCLC<br \/>\n      demonstrated a confirmed ORR of 33.3 percent (n=8\/24) (95% CI,<br \/>\n      15.6%-55.3%), including one complete response and seven partial<br \/>\n      responses. One patient had stable disease and 13 patients had<br \/>\n      progressive disease. Responses were durable, with a median duration of<br \/>\n      response of 19.4 months (95% CI, range: 3.6+ to 20.0+).\n    <\/p>\n<p>\n      Additionally, the median PFS was 1.9 months (95% CI, 1.7-5.9), with a<br \/>\n      six-month PFS rate of 28.6 percent and 12-month PFS rate of 23.8<br \/>\n      percent. The median OS was 9.7 months (95% CI, 4.1-NR), with a six-month<br \/>\n      OS rate of 66.0 percent and a 12-month OS rate of 37.7 percent.\n    <\/p>\n<p>\n      The safety profile of KEYTRUDA was consistent with that observed in<br \/>\n      previously reported studies.&nbsp;Grade 3-5 treatment-related adverse events<br \/>\n      were asthenia, blood bilirubin increased, colitis and intestinal<br \/>\n      ischemia (n=1 for all). Some patients experienced adverse events of<br \/>\n      special interest, including autoimmune thyroiditis, infusion site<br \/>\n      reaction, cytokine release syndrome and colitis (n=1 for all).\n    <\/p>\n<p>\n      \u201cThese long-term data, which show meaningful response rates and durable<br \/>\n      responses in certain patients with small cell lung cancer, are<br \/>\n      encouraging,\u201d said Dr. Ott. \u201cWith these findings, we are advancing<br \/>\n      understanding of the potential for immunotherapy to make a difference<br \/>\n      for these patients.\u201d\n    <\/p>\n<p>\n      <b>Results from KEYNOTE-028 Malignant Pleural Mesothelioma Cohort<br \/>\n      (Abstract #OA13.03)<\/b>\n    <\/p>\n<p>\n      Data from the malignant pleural mesothelioma cohort of the KEYNOTE-028<br \/>\n      trial were presented in an oral presentation on Dec. 6 by Dr. Evan<br \/>\n      Alley, Abramson Cancer Center, University of Pennsylvania.\n    <\/p>\n<p>\n      Results showed a confirmed ORR of 20.0 percent (n=5\/25) (95% CI,<br \/>\n      6.8-40.7). All responses were partial responses and 13 patients had<br \/>\n      stable disease. The median duration of response was 12.0 months (range,<br \/>\n      3.7-20.5+). In total, 60.9 percent of evaluable patients experienced a<br \/>\n      decrease in tumor size.\n    <\/p>\n<p>\n      Additionally, the median PFS was 5.4 months (95% CI, 3.4-7.5), with a<br \/>\n      six-month PFS rate of 45.8 percent and a 12-month PFS rate of 20.8<br \/>\n      percent. Median OS was 18.0 months (95% CI, 9.4-NR), with a six-month OS<br \/>\n      rate of 83.5 percent and a 12-month OS rate of 62.6 percent.\n    <\/p>\n<p>\n      The safety profile of KEYTRUDA (pembrolizumab) was consistent with that<br \/>\n      observed in previously reported studies.&nbsp;Grade 3 treatment-related<br \/>\n      adverse events were ALT increase, appetite decrease, dyspnea,<br \/>\n      iridocyclitis, neutrophil count decreased, pyrexia and thrombocytopenia<br \/>\n      (n=1 for all). Some patients experienced adverse events of special<br \/>\n      interest, including erythema\/erythema multiforme, hypothyroidism,<br \/>\n      infusion-related reaction, iridocyclitis and rhabdomyolysis (n=1 for<br \/>\n      all). There were no Grade 4 or 5 treatment-related adverse events and no<br \/>\n      treatment-related deaths.\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (pembrolizumab)<\/b>\n    <\/p>\n<p>\n      KEYTRUDA is a humanized monoclonal antibody that works by increasing the<br \/>\n      ability of the body\u2019s immune system to help detect and fight tumor<br \/>\n      cells. KEYTRUDA blocks the interaction between PD-1 and its ligands,<br \/>\n      PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both<br \/>\n      tumor cells and healthy cells.\n    <\/p>\n<p>\n      KEYTRUDA is administered as an intravenous infusion over 30 minutes<br \/>\n      every three weeks for the approved indications. KEYTRUDA for injection<br \/>\n      is supplied in a 100 mg single use vial.\n    <\/p>\n<p>\n      <b>KEYTRUDA (pembrolizumab)<\/b> <b>Indications and Dosing<\/b>\n    <\/p>\n<p>\n      <i>Melanoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with unresectable or<br \/>\n      metastatic melanoma at a dose of 2 mg\/kg every three weeks until disease<br \/>\n      progression or unacceptable toxicity.\n    <\/p>\n<p>\n      <i>Lung Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the first-line treatment of patients with<br \/>\n      metastatic non-small cell lung cancer (NSCLC) whose tumors have high<br \/>\n      PD-L1 expression [tumor proportion score (TPS) \u226550%] as determined by an<br \/>\n      FDA-approved test, with no EGFR or ALK genomic tumor aberrations.\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) is also indicated for the treatment of patients<br \/>\n      with metastatic NSCLC whose tumors express PD-L1 (TPS \u22651%) as determined<br \/>\n      by an FDA-approved test, with disease progression on or after<br \/>\n      platinum-containing chemotherapy. Patients with EGFR or ALK genomic<br \/>\n      tumor aberrations should have disease progression on FDA-approved<br \/>\n      therapy for these aberrations prior to receiving KEYTRUDA.\n    <\/p>\n<p>\n      In metastatic NSCLC, KEYTRUDA is administered at a fixed dose of 200 mg<br \/>\n      every three weeks until disease progression, unacceptable toxicity, or<br \/>\n      up to 24 months in patients without disease progression.\n    <\/p>\n<p>\n      <i>Head and Neck Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent or<br \/>\n      metastatic head and neck squamous cell carcinoma (HNSCC) with disease<br \/>\n      progression on or after platinum-containing chemotherapy. This<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. In HNSCC, KEYTRUDA is<br \/>\n      administered at a fixed dose of 200 mg every three weeks until disease<br \/>\n      progression, unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup>&nbsp;<b>(pembrolizumab)<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated pneumonitis, including fatal cases.<br \/>\n      Pneumonitis occurred in 94 (3.4%) of 2799 patients receiving KEYTRUDA,<br \/>\n      including Grade 1 (0.8%), 2 (1.3%), 3 (0.9%), 4 (0.3%), and 5 (0.1%)<br \/>\n      pneumonitis, and occurred more frequently in patients with a history of<br \/>\n      prior thoracic radiation (6.9%) compared to those without (2.9%).<br \/>\n      Monitor patients for signs and symptoms of pneumonitis. Evaluate<br \/>\n      suspected pneumonitis with radiographic imaging. Administer<br \/>\n      corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 or<br \/>\n      recurrent Grade 2 pneumonitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated colitis. Colitis occurred in 48<br \/>\n      (1.7%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.4%), 3<br \/>\n      (1.1%), and 4 (&lt;0.1%) colitis. Monitor patients for signs and symptoms<br \/>\n      of colitis. Administer corticosteroids for Grade 2 or greater colitis.<br \/>\n      Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue KEYTRUDA for<br \/>\n      Grade 4 colitis.\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) can cause immune-mediated hepatitis. Hepatitis<br \/>\n      occurred in 19 (0.7%) of 2799 patients receiving KEYTRUDA, including<br \/>\n      Grade 2 (0.1%), 3 (0.4%), and 4 (&lt;0.1%) hepatitis. Monitor patients for<br \/>\n      changes in liver function. Administer corticosteroids for Grade 2 or<br \/>\n      greater hepatitis and, based on severity of liver enzyme elevations,<br \/>\n      withhold or discontinue KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA can cause hypophysitis. Hypophysitis occurred in 17 (0.6%) of<br \/>\n      2799 patients receiving KEYTRUDA, including Grade 2 (0.2%), 3 (0.3%),<br \/>\n      and 4 (&lt;0.1%) hypophysitis. Monitor patients for signs and symptoms of<br \/>\n      hypophysitis (including hypopituitarism and adrenal insufficiency).<br \/>\n      Administer corticosteroids and hormone replacement as clinically<br \/>\n      indicated. Withhold KEYTRUDA for Grade 2; withhold or discontinue for<br \/>\n      Grade 3 or 4 hypophysitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause thyroid disorders, including hyperthyroidism,<br \/>\n      hypothyroidism, and thyroiditis. Hyperthyroidism occurred in 96 (3.4%)<br \/>\n      of 2799 patients receiving KEYTRUDA, including Grade 2 (0.8%) and 3<br \/>\n      (0.1%) hyperthyroidism. Hypothyroidism occurred in 237 (8.5%) of 2799<br \/>\n      patients receiving KEYTRUDA, including Grade 2 (6.2%) and 3 (0.1%)<br \/>\n      hypothyroidism. The incidence of new or worsening hypothyroidism was<br \/>\n      higher in patients with HNSCC occurring in 28 (15%) of 192 patients with<br \/>\n      HNSCC, including Grade 3 (0.5%) hypothyroidism. Thyroiditis occurred in<br \/>\n      16 (0.6%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.3%)<br \/>\n      thyroiditis. Monitor patients for changes in thyroid function (at the<br \/>\n      start of treatment, periodically during treatment, and as indicated<br \/>\n      based on clinical evaluation) and for clinical signs and symptoms of<br \/>\n      thyroid disorders. Administer replacement hormones for hypothyroidism<br \/>\n      and manage hyperthyroidism with thionamides and beta-blockers as<br \/>\n      appropriate. Withhold or discontinue KEYTRUDA for Grade 3 or 4<br \/>\n      hyperthyroidism.\n    <\/p>\n<p>\n      KEYTRUDA can cause type 1 diabetes mellitus, including diabetic<br \/>\n      ketoacidosis, which have been reported in 6 (0.2%) of 2799 patients.<br \/>\n      Monitor patients for hyperglycemia or other signs and symptoms of<br \/>\n      diabetes. Administer insulin for type 1 diabetes, and withhold KEYTRUDA<br \/>\n      and administer antihyperglycemics in patients with severe hyperglycemia.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated nephritis. Nephritis occurred in 9<br \/>\n      (0.3%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.1%), and 4 (&lt;0.1%) nephritis. Monitor patients for changes in renal<br \/>\n      function. Administer corticosteroids for Grade 2 or greater nephritis.<br \/>\n      Withhold KEYTRUDA for Grade 2; permanently discontinue KEYTRUDA for<br \/>\n      Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      KEYTRUDA can cause other clinically important immune-mediated adverse<br \/>\n      reactions. For suspected immune-mediated adverse reactions, ensure<br \/>\n      adequate evaluation to confirm etiology or exclude other causes. Based<br \/>\n      on the severity of the adverse reaction, withhold KEYTRUDA<br \/>\n      (pembrolizumab) and administer corticosteroids. Upon improvement to<br \/>\n      Grade 1 or less, initiate corticosteroid taper and continue to taper<br \/>\n      over at least 1 month. Based on limited data from clinical studies in<br \/>\n      patients whose immune-related adverse reactions could not be controlled<br \/>\n      with corticosteroid use, administration of other systemic<br \/>\n      immunosuppressants can be considered. Resume KEYTRUDA when the adverse<br \/>\n      reaction remains at Grade 1 or less following corticosteroid taper.<br \/>\n      Permanently discontinue KEYTRUDA for any Grade 3 immune-mediated adverse<br \/>\n      reaction that recurs and for any life-threatening immune-mediated<br \/>\n      adverse reaction.\n    <\/p>\n<p>\n      The following clinically significant immune-mediated adverse reactions<br \/>\n      occurred in less than 1% (unless otherwise indicated) of 2799 patients:<br \/>\n      arthritis (1.5%), exfoliative dermatitis, bullous pemphigoid, rash<br \/>\n      (1.4%), uveitis, myositis, Guillain-Barr\u00e9 syndrome, myasthenia gravis,<br \/>\n      vasculitis, pancreatitis, hemolytic anemia, and partial seizures arising<br \/>\n      in a patient with inflammatory foci in brain parenchyma.\n    <\/p>\n<p>\n      KEYTRUDA can cause severe or life-threatening infusion-related<br \/>\n      reactions, which have been reported in 6 (0.2%) of 2799 patients.<br \/>\n      Monitor patients for signs and symptoms of infusion-related reactions,<br \/>\n      including rigors, chills, wheezing, pruritus, flushing, rash,<br \/>\n      hypotension, hypoxemia, and fever. For Grade 3 or 4 reactions, stop<br \/>\n      infusion and permanently discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA can cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      In KEYNOTE-006, KEYTRUDA was discontinued due to adverse reactions in 9%<br \/>\n      of 555 patients with advanced melanoma; adverse reactions leading to<br \/>\n      discontinuation in more than one patient were colitis (1.4%), autoimmune<br \/>\n      hepatitis (0.7%), allergic reaction (0.4%), polyneuropathy (0.4%), and<br \/>\n      cardiac failure (0.4%). Adverse reactions leading to interruption of<br \/>\n      KEYTRUDA occurred in 21% of patients; the most common (\u22651%) was diarrhea<br \/>\n      (2.5%). The most common adverse reactions with KEYTRUDA vs ipilimumab<br \/>\n      were fatigue (28% vs 28%), diarrhea (26% with KEYTRUDA), rash (24% vs<br \/>\n      23%), and nausea (21% with KEYTRUDA). Corresponding incidence rates are<br \/>\n      listed for ipilimumab only for those adverse reactions that occurred at<br \/>\n      the same or lower rate than with KEYTRUDA.\n    <\/p>\n<p>\n      In KEYNOTE-002, KEYTRUDA was discontinued due to adverse reactions in<br \/>\n      12% of 357 patients with advanced melanoma; the most common (\u22651%) were<br \/>\n      general physical health deterioration (1%), asthenia (1%), dyspnea (1%),<br \/>\n      pneumonitis (1%), and generalized edema (1%). Adverse reactions leading<br \/>\n      to interruption of KEYTRUDA (pembrolizumab) occurred in 14% of patients;<br \/>\n      the most common (\u22651%) were dyspnea (1%), diarrhea (1%), and<br \/>\n      maculopapular rash (1%). The most common adverse reactions with KEYTRUDA<br \/>\n      vs chemotherapy were fatigue (43% with KEYTRUDA), pruritus (28% vs 8%),<br \/>\n      rash (24% vs 8%), constipation (22% vs 20%), nausea (22% with KEYTRUDA),<br \/>\n      diarrhea (20% vs 20%), and decreased appetite (20% with KEYTRUDA).<br \/>\n      Corresponding incidence rates are listed for chemotherapy only for those<br \/>\n      adverse reactions that occurred at the same or lower rate than with<br \/>\n      KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA was discontinued due to adverse reactions in 8% of 682 patients<br \/>\n      with metastatic NSCLC. The most common adverse event resulting in<br \/>\n      permanent discontinuation of KEYTRUDA was pneumonitis (1.8%). Adverse<br \/>\n      reactions leading to interruption of KEYTRUDA occurred in 23% of<br \/>\n      patients; the most common (\u22651%) were diarrhea (1%), fatigue (1.3%),<br \/>\n      pneumonia (1%), liver enzyme elevation (1.2%), decreased appetite<br \/>\n      (1.3%), and pneumonitis (1%). The most common adverse reactions<br \/>\n      (occurring in at least 20% of patients and at a higher incidence than<br \/>\n      with docetaxel) were decreased appetite (25% vs 23%), dyspnea (23% vs<br \/>\n      20%), and nausea (20% vs 18%).\n    <\/p>\n<p>\n      KEYTRUDA was discontinued due to adverse reactions in 17% of 192<br \/>\n      patients with HNSCC. Serious adverse reactions occurred in 45% of<br \/>\n      patients. The most frequent serious adverse reactions reported in at<br \/>\n      least 2% of patients were pneumonia, dyspnea, confusional state,<br \/>\n      vomiting, pleural effusion, and respiratory failure. The most common<br \/>\n      adverse reactions (reported in at least 20% of patients) were fatigue,<br \/>\n      decreased appetite, and dyspnea. Adverse reactions occurring in patients<br \/>\n      with HNSCC were generally similar to those occurring in patients with<br \/>\n      melanoma or NSCLC, with the exception of increased incidences of facial<br \/>\n      edema (10% all Grades; 2.1% Grades 3 or 4) and new or worsening<br \/>\n      hypothyroidism.\n    <\/p>\n<p>\n      It is not known whether KEYTRUDA is excreted in human milk. Because many<br \/>\n      drugs are excreted in human milk, instruct women to discontinue nursing<br \/>\n      during treatment with KEYTRUDA and for 4 months after the final dose.\n    <\/p>\n<p>\n      Safety and effectiveness of KEYTRUDA have not been established in<br \/>\n      pediatric patients.\n    <\/p>\n<p>\n      <b>Our Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck, helping people<br \/>\n      fight cancer is our passion and supporting accessibility to our cancer<br \/>\n      medicines is our commitment. Our focus is on pursuing research in<br \/>\n      immuno-oncology and we are accelerating every step in the journey \u2013 from<br \/>\n      lab to clinic \u2013 to potentially bring new hope to people with cancer.\n    <\/p>\n<p>\n      As part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the fastest-growing development<br \/>\n      programs in the industry. We are currently executing an expansive<br \/>\n      research program that includes nearly 400 clinical trials evaluating our<br \/>\n      anti-PD-1 therapy across more than 30 tumor types. We also continue to<br \/>\n      strengthen our immuno-oncology portfolio through strategic acquisitions<br \/>\n      and are prioritizing the development of several promising<br \/>\n      immunotherapeutic candidates with the potential to improve the treatment<br \/>\n      of advanced cancers.\n    <\/p>\n<p>\n      For more information about our oncology clinical trials, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51472350&amp;newsitemid=20161206005400&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=1&amp;md5=5c2a8c3ec1770aa41d051c7a1dfc6503\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For 125 years, Merck has been a global health care leader working to<br \/>\n      help the world be well. Merck is known as MSD outside the United States<br \/>\n      and Canada. Through our prescription medicines, vaccines, biologic<br \/>\n      therapies, and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      health care through far-reaching policies, programs and partnerships.<br \/>\n      For more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51472350&amp;newsitemid=20161206005400&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=c3e00b7a68145370f9248e43baf50406\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51472350&amp;newsitemid=20161206005400&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=1f8547754b883dcab55a21569628e740\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51472350&amp;newsitemid=20161206005400&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=4b223bde32ed014c53800b61237c90ad\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51472350&amp;newsitemid=20161206005400&amp;lan=en-US&amp;anchor=YouTube&amp;index=5&amp;md5=4b7c64f6d2ee4aaf761a9a1d83f1a7c3\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51472350&amp;newsitemid=20161206005400&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=6&amp;md5=e7fd01c5a1a06a4436e0d4a251ff8166\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2015 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51472350&amp;newsitemid=20161206005400&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=7&amp;md5=601c5524f6e8c6c83b8dfbba5d1843e0\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51472350&amp;newsitemid=20161206005400&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=8&amp;md5=22aa82b42f763f44ee3db4b50365c081\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<b>&nbsp;and<\/b>\n    <\/p>\n<p>\n      <b>Patient Information\/Medication Guide for KEYTRUDA at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51472350&amp;newsitemid=20161206005400&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=9&amp;md5=c73c48907e4465b5ff873a4b0444bd7d\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><br \/>\n<\/a><br \/>\n<b>.<\/b>\n    <\/p>\n<\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20161206005400r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Media:<br \/>Pamela Eisele, 267-305-3558<br \/>or<br \/>Courtney Ronaldo,        908-236-1108<br \/>or<br \/>Investors<br \/>Teri Loxam, 908-740-1986<br \/>or<br \/>Amy        Klug, 908-740-1898     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that updated findings from the phase 1b KEYNOTE-028 study investigating the use of KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, in previously treated patients with advanced small cell lung cancer (SCLC) and malignant pleural mesothelioma, showed clinical activity and durable responses in some patients. These data were featured in oral presentations at the 17 th World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer. \u201cAs data from our initial trials exploring KEYTRUDA mature, we are encouraged to see durable clinical activity in difficult-to-treat cancers such as small cell lung cancer and malignant pleural mesothelioma, where new treatments are clearly needed,\u201d said Dr. Roger Dansey, senior vice president and therapeutic area head, oncology late-stage development, Merck Research Laboratories. \u201cWith our extensive immuno-oncology research<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,138,55,289],"class_list":["post-745289","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-oncology-newsroom","tag-prescription-medicine-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Updated KEYTRUDA\u00ae (pembrolizumab) Data in Small Cell Lung Cancer and Mesothelioma Presented at 17th World Conference on Lung Cancer - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/updated-keytruda-pembrolizumab-data-in-small-cell-lung-cancer-and-mesothelioma-presented-at-17th-world-conference-on-lung-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Updated KEYTRUDA\u00ae (pembrolizumab) Data in Small Cell Lung Cancer and Mesothelioma Presented at 17th World Conference on Lung Cancer - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that updated findings from the phase 1b KEYNOTE-028 study investigating the use of KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, in previously treated patients with advanced small cell lung cancer (SCLC) and malignant pleural mesothelioma, showed clinical activity and durable responses in some patients. These data were featured in oral presentations at the 17 th World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer. \u201cAs data from our initial trials exploring KEYTRUDA mature, we are encouraged to see durable clinical activity in difficult-to-treat cancers such as small cell lung cancer and malignant pleural mesothelioma, where new treatments are clearly needed,\u201d said Dr. Roger Dansey, senior vice president and therapeutic area head, oncology late-stage development, Merck Research Laboratories. \u201cWith our extensive immuno-oncology research\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/updated-keytruda-pembrolizumab-data-in-small-cell-lung-cancer-and-mesothelioma-presented-at-17th-world-conference-on-lung-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"14 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/updated-keytruda-pembrolizumab-data-in-small-cell-lung-cancer-and-mesothelioma-presented-at-17th-world-conference-on-lung-cancer\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/updated-keytruda-pembrolizumab-data-in-small-cell-lung-cancer-and-mesothelioma-presented-at-17th-world-conference-on-lung-cancer\\\/\",\"name\":\"Updated KEYTRUDA\u00ae (pembrolizumab) Data in Small Cell Lung Cancer and Mesothelioma Presented at 17th World Conference on Lung Cancer - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2016-12-06T08:20:00+00:00\",\"dateModified\":\"2025-11-07T06:25:29+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/updated-keytruda-pembrolizumab-data-in-small-cell-lung-cancer-and-mesothelioma-presented-at-17th-world-conference-on-lung-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/updated-keytruda-pembrolizumab-data-in-small-cell-lung-cancer-and-mesothelioma-presented-at-17th-world-conference-on-lung-cancer\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/updated-keytruda-pembrolizumab-data-in-small-cell-lung-cancer-and-mesothelioma-presented-at-17th-world-conference-on-lung-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Updated KEYTRUDA\u00ae (pembrolizumab) Data in Small Cell Lung Cancer and Mesothelioma Presented at 17th World Conference on Lung Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Updated KEYTRUDA\u00ae (pembrolizumab) Data in Small Cell Lung Cancer and Mesothelioma Presented at 17th World Conference on Lung Cancer - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/updated-keytruda-pembrolizumab-data-in-small-cell-lung-cancer-and-mesothelioma-presented-at-17th-world-conference-on-lung-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Updated KEYTRUDA\u00ae (pembrolizumab) Data in Small Cell Lung Cancer and Mesothelioma Presented at 17th World Conference on Lung Cancer - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that updated findings from the phase 1b KEYNOTE-028 study investigating the use of KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, in previously treated patients with advanced small cell lung cancer (SCLC) and malignant pleural mesothelioma, showed clinical activity and durable responses in some patients. These data were featured in oral presentations at the 17 th World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer. \u201cAs data from our initial trials exploring KEYTRUDA mature, we are encouraged to see durable clinical activity in difficult-to-treat cancers such as small cell lung cancer and malignant pleural mesothelioma, where new treatments are clearly needed,\u201d said Dr. Roger Dansey, senior vice president and therapeutic area head, oncology late-stage development, Merck Research Laboratories. \u201cWith our extensive immuno-oncology research","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/updated-keytruda-pembrolizumab-data-in-small-cell-lung-cancer-and-mesothelioma-presented-at-17th-world-conference-on-lung-cancer\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:29+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"14 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/updated-keytruda-pembrolizumab-data-in-small-cell-lung-cancer-and-mesothelioma-presented-at-17th-world-conference-on-lung-cancer\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/updated-keytruda-pembrolizumab-data-in-small-cell-lung-cancer-and-mesothelioma-presented-at-17th-world-conference-on-lung-cancer\/","name":"Updated KEYTRUDA\u00ae (pembrolizumab) Data in Small Cell Lung Cancer and Mesothelioma Presented at 17th World Conference on Lung Cancer - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2016-12-06T08:20:00+00:00","dateModified":"2025-11-07T06:25:29+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/updated-keytruda-pembrolizumab-data-in-small-cell-lung-cancer-and-mesothelioma-presented-at-17th-world-conference-on-lung-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/updated-keytruda-pembrolizumab-data-in-small-cell-lung-cancer-and-mesothelioma-presented-at-17th-world-conference-on-lung-cancer\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/updated-keytruda-pembrolizumab-data-in-small-cell-lung-cancer-and-mesothelioma-presented-at-17th-world-conference-on-lung-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Updated KEYTRUDA\u00ae (pembrolizumab) Data in Small Cell Lung Cancer and Mesothelioma Presented at 17th World Conference on Lung Cancer"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"8415c072-6cd2-4cbd-a2ac-edeb3b885fb5","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Updated-KEYTRUDA-pembrolizumab-Data-in-Small-Cell-Lung-Cancer-and-Mesothelioma-Presented-at-17th-World-Conference-on-Lung-Cancer-2016.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745289","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745289\/revisions"}],"predecessor-version":[{"id":3674701,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745289\/revisions\/3674701"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745289"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745289"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}